Incidence of and risk factors for severe hepatotoxicity of nelfinavir-containing regimens among HIV-infected patients with chronic hepatitis C

Journal of Antimicrobial Chemotherapy

Volumn 58, Issue 1, 2006, Pages 140-146

  Mira, José A ^a   Macías, Juan ^a   Girón González, José A ^b   Merino, Dolores ^c   González Serrano, Mercedes ^d   Jiménez Mejías, Manuel E ^e   Caballero Granado, Francisco J ^f   Torre Cisneros, Julián ^g   Terrón, Alberto ^h   Becker, Mark I ⁱ   Gómez Mateos, Jesús ^a   Arizcorreta Yarza, Ana ^b   Pineda, Juan A ^a  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^b HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

^c HOSPITAL JUAN RAMÓN JIMÉNEZ   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^f HOSPITAL PUNTA DE EUROPA   (Spain)

^g HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^h Hospital del SAS   (Spain)

ⁱ HOFFMANN LA ROCHE INC   (United States)

Author keywords

Liver fibrosis; Liver toxicity; Nevirapine; Protease inhibitors

Indexed keywords

ABACAVIR; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; COTRIMOXAZOLE; DIDANOSINE; EFAVIRENZ; GAMMA GLUTAMYLTRANSFERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISONIAZID; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PYRAZINAMIDE; RIFAMPICIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; TUBERCULOSTATIC AGENT; ZIDOVUDINE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; HYPERBILIRUBINEMIA; INCIDENCE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDY; RISK FACTOR; SUPERINFECTION;

ADULT; ANTI-HIV AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HEPATITIS, TOXIC; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; NELFINAVIR; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 33748079782     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl214     Document Type: Article

References (29)

1. den Brinker M, Wit FW, Wertheim-van Dillen PM et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000; 14: 2895-902.
2. Rodríguez-Rosado R, García-Samaniego J, Soriano V. Hepatotoxicity after introduction of highly active antiretroviral therapy. AIDS 1998; 12: 1256.
3. Gisolf EH, Dreezen C, Danner SA et al. Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine. Clin Infect Dis 2000; 31: 1234-9.
4. Sulkowski MS, Thomas DL, Chaisson RE et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283: 74-80.
5. Saves M, Raffi F, Clevenbergh P et al. Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO Study Group. Antimicrob Agents Chemother 2000; 44: 3451-5.
6. Sulkowski MS, Mehta SH, Chaisson RE et al. Hepatotoxicity associated with protease inhibitor-based antiretroviral therapy regimens with or without concurrent ritonavir. AIDS 2004; 18: 2277-84.
7. Aceti A, Pasquazzi C, Zechini B et al. Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: The role of hepatitis B and C virus infection. J Acquir Immune Defic Syndr 2002; 29: 41-8.
8. Lana R, Núñez M, Mendoza JL et al. Rate and risk factors of liver toxicity in patients receiving antiretroviral therapy. Med Clin (Barc) 2001; 117: 607-10.
9. Aranzabal L, Casado JL, Moya J et al. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 2005; 40: 588-93.
10. Macías J, Castellano V, Merchante N et al. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: Harmful impact of nevirapine. AIDS 2004; 18: 767-74.
11. Mehta SH, Thomas DL, Torbenson M et al. The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection. Hepatology 2005; 41: 123-31.
12. Sanne I, Mommeja-Marin H, Hinkle J et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis 2005; 191: 825-9.
13. Martín-Carbonero L, Núnez M, González-Lahoz J et al. Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine. HIV Clin Trials 2003; 4: 115-20.
14. Macías J, Melguizo I, Fernández-Rivera FJ et al. Mortality due to liver failure and impact on survival of hepatitis virus infections in HIV-infected patients receiving potent antiretroviral therapy. Eur J Clin Microbiol Infect Dis 2002; 21: 775-81.
15. Martínez-Sierra C, Arizcorreta A, Díaz F et al. Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis 2003; 36: 491-8.
16. Scheuer PJ. Classification of chronic viral hepatitis: A need for reassessment. J Hepatol 1991; 13: 372-4.
17. da Silva B, King M, Cernohous P et al. Lopinavir/ritonavir (LPV/r) safety, tolerability and efficacy in hepatitis C and/or hepatitis B-infected patients: Review of clinical trials. In: Program and Abstracts of the Fifteenth International AIDS Conference, Bangkok, Thailand, 2004. Abstract MoPeB3285, p. 54. IAS International AIDS Society, Geneva, Switzerland.
18. Sabin CA. Pitfalls of assessing hepatotoxicity in trials and observational cohorts. Clin Infect Dis 2004; 38: S56-64.
19. AIDS Clinical Trials Group. Table of Grading Severity of Adult Adverse Experiences. Rockville, MD: US Division of AIDS, National Institute of Allergy and Infectious Diseases, 1996.
20. Sulkowski MS, Thomas DL, Mehta SH et al. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: Role of hepatitis C and B infections. Hepatology 2002; 35: 182-9.
21. Dieterich DT, Robinson PA, Love J et al. Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors. Clin Infect Dis 2004; 38: S80-9.
22. Law WP, Dore GJ, Duncombe CJ et al. Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001. AIDS 2003; 17: 2191-9.
23. Skowron G, Leoung G, Hall DB et al. Pharmacokinetic evaluation and short-term activity of stavudine, nevirapine, and nelfinavir therapy in HIV-1-infected adults. J Acquir Immune Defic Syndr 2004; 35: 351-8.
24. Merry C, Barry MG, Mulcahy F et al. The pharmacokinetics of combination therapy with nelfinavir plus nevirapine. AIDS 1998; 12: 1163-7.
25. Poynard T, Ratziu V, Charlotte F et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001; 34: 730-9.
26. Sulkowski M, Mehta S, Torbenson M et al. Unexpected significant liver disease among HIV/HCV-co-infected persons with minimal fibrosis on initial liver biopsy. In: Program and Abstracts of the Twelfth Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2005. Abstract 121, p. 16. National Institute of Allergy and Infectious Diseases and Centers for Disease Control and Prevention, USA.
27. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 1449-57.
28. Benhamou Y, Di Martino V, Bochet M et al. Factors affecting liver fibrosis in human immunodefiency virus- and hepatitis C virus-coinfected patients: Impact of protease inhibitor therapy. Hepatology 2001; 34: 283-7.
29. Marine-Barjoan E, Saint-Paul MC, Pradier C et al. Impact of antiretroviral treatment on progression of hepatic fibrosis in HIV/ hepatitis C virus co-infected patients. AIDS 2004; 18: 2163-70.